



MEMORANDUM

To: All Regional Medical Laboratory, Inc. (RML) Clients

From: Regional Medical Laboratory, Inc.
Jennifer Tune, MT (ASCP), MS HCA, Director of Ancillary Services
Joshua Freitag, BA, Manager of Revenue Cycle Management

Date: April 19, 2019

Subject: Coverage of Molecular Vaginal Pathogen Testing

Regional Medical Laboratory recently introduced MySwab™, a group of molecular tests specifically designed to target the most common genital pathogens affecting women's health and sexually transmitted diseases. MySwab™ testing is comprehensive, cost effective and reliable while simplifying collection through requiring a single swab.

MySwab™ can detect the following vaginal pathogens:

Bacterial Vaginosis	Candida Vaginitis	Sexually Transmitted Pathogens
<ul style="list-style-type: none"> • Gardnerella vaginalis • Lactobacillus species 	<ul style="list-style-type: none"> • C. albicans • C. tropicalis • C. dubliniensis • C. parapsilosis • C. glabrata 	<ul style="list-style-type: none"> • Chlamydia trachomatis • Neisseria gonorrhoeae • Trichomonas vaginalis • Herpes Simplex Virus 1 and 2

The Bacterial and Candida Vaginosis components of the MySwab™ test were developed and validated for clinical use by Regional Medical Laboratory using methods defined by the Clinical Laboratory Improvement Act and by the College of American Pathologists. Clinical utility of this testing is supported by numerous peer reviewed publications. Despite these facts, and the significant number of insurers covering this testing, molecular testing for Bacterial and Candida Vaginosis has been classified by a few insurers as experimental and CPT codes 87512, 87799 and 87481 may not be covered. Please check with your patient's insurer if you have questions regarding coverage.

Please contact your RML Account Representative if you have questions regarding this communication.